Hard Numbers: Gershkovich's appeal, atomic mosquitoes, China’s AI gun, IS v. truffle hunters, Europe’s “Tiny Olympics”
Argentina is fighting its worst dengue epidemic in years by sterilizing male mosquitoes with DNA-altering radiation.
1: For the first time since his arrest on March 29, jailed Wall Street Journal reporter Evan Gershkovich has appeared in public in a Moscow courtroom. Gershkovich appeared in good spirits as he appealed his pre-trial detention, though no decision has been handed down. At the same time, Vladimir Putin was visiting Russian occupied areas of Kherson and the Luhansk region.
10,000: Argentina is fighting its worst dengue epidemic in years by … zapping 10,000 male mosquitoes per week with DNA-altering radiation that sterilizes the insects. Using radiation to tinker with the DNA of one of the world's most common insects and carrier of a potentially deadly disease, what could go wrong?
9.9: The Chinese military is developing an artificial intelligence-powered, laser-guided artillery gun that researchers claim will be able to hit a human-sized target with an artillery shell from 9.9 miles away. This "smart artillery" could help China carry out precision strikes on urban targets without using missiles, minimizing collateral damage in a hypothetical attack on Taiwan.
26: Truffle hunting, once a cherished pastime in Syria, has become a deadly gamble in parts of the country controlled by the Islamic State. Twenty-six people were killed Sunday in an attack by IS militants while looking for the prized fungus, a kilogram of which can fetch more than the average Syrian monthly salary.
<1 million: Feel left out of Olympic glory because your country is too small to qualify for anything? Well, if you're a citizen of one of Europe's nine microstates (with a population under 1 million), you're in luck. Next month, Malta is hosting the 3rd edition of the Games of Small States of Europe, aka the "Tiny Olympics," where you'll have a much better shot at the podium. Just don't mind the weird mascot.
Dive deeper with our top stories and analysis.
Privacy notice: By signing up, I acknowledge that I have read, understand, and consent to the Privacy Policy and Terms of Use, including the transfer of my personal data to the United States from my country of residence (if different).



